Pharmaceutical Medicine

, Volume 24, Issue 5, pp 295–300 | Cite as

European Society of Cardiology Congress 2010

28 August–1 September 2010; Stockholm, Sweden
  • Mary Ellen Kitler
Meeting Report


Atrial Fibrillation Angiotensin Convert Enzyme Inhibitor Perindopril Coffee Consumption Stable Coronary Artery Disease 



Dr Kitler is a consultant at Associates for Business and Research, which specializes in all issues relating to the pharmaceutical and biotechnology industries and relating to public health.


  1. 1.
    Lü scher TF, Brugada J, Gersh BJ, et al., editors. European Society of Cardiology Congress, 2010 special ed. Eur Heart J 2010 Sep; 31 (abstract suppl.). ESC Congress 2010; 28 Aug-1 Sep; StockholmGoogle Scholar
  2. 2.
    European Society of Cardiology. Cardiovascular medicine: compendium of abridged ESC guidelines 2010. London: Springer Healthcare, 2010Google Scholar
  3. 3.
    European Society of Cardiology. tESC guidelines for the management of grownup congenital heart disease. Eur Heart J [online]. Available from URL: [Accessed 2010 Sep 14]
  4. 4.
    European Society of Cardiology. ESC guidelines on myocardial revascularization. Eur Heart J [online]. Available from URL: [Accessed 2010 Sep 14]
  5. 5.
    European Society of Cardiology. ESC guidelines for the management of atrial fibrillation. EurHeart J [online]. Available fromURL: [Accessed 2010 Sep 14]
  6. 6.
    European Society of Cardiology. 2010 focused update of ESC guidelines on device therapy in heart failure. Eur Heart J [online]. Available from URL: [Accessed 2010 Sep 14]
  7. 7.
    Jasper JB, Issacs A, Boersmal E, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J 2010; 31 (5): 1854–64CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Mary Ellen Kitler
    • 1
  1. 1.Associates for Business and ResearchRolleSwitzerland

Personalised recommendations